Roth Capital Resumes BioLineRx (BLRX) at Buy
Tweet
Share
E-mailGet Alerts BLRX Hot Sheet
Price: $3.24 +2.53%
Rating Summary:
6 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 2 | Down: 3 | New: 4
Rating Summary:
6 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 2 | Down: 3 | New: 4
Join SI Premium – FREE
Roth Capital resumed coverage on BioLineRx (NASDAQ: BLRX) with a Buy rating and a price target of $8.00.
For an analyst ratings summary and ratings history on BioLineRx click here. For more ratings news on BioLineRx click here.
Shares of BioLineRx closed at $2.06 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Upgrades QIAGEN NV (QIA:GR) (QGEN) to Overweight
- JPMorgan Starts Nippon Life India Asset Management Ltd (NAM:IN) at Overweight
- Morgan Stanley Upgrades Demant A/S (DEMANT:DC) (WILYY) to Overweight
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
